Literature DB >> 12050351

Uterine sarcoma associated with tamoxifen use.

Diane K Wysowski, Susan Flamm Honig, Julie Beitz.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050351     DOI: 10.1056/NEJM200206063462319

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  19 in total

1.  Adverse drug event monitoring at the Food and Drug Administration.

Authors:  Syed Rizwanuddin Ahmad
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

Review 2.  High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches.

Authors:  Charles-André Philip; Patricia Pautier; Florence Duffaud; Isabelle Ray-Coquard
Journal:  Curr Oncol Rep       Date:  2014-10       Impact factor: 5.075

Review 3.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

Review 4.  Ductal carcinoma in situ: a brief review of treatment variation and impacts on patients and society.

Authors:  Christine Vatovec; Mujde Z Erten; Jane Kolodinsky; Phil Brown; Marie Wood; Ted James; Brian L Sprague
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2014       Impact factor: 1.807

5.  Role of aromatase inhibitors in the upfront adjuvant hormonal therapy of postmenopausal patients with breast cancer.

Authors:  Jean-Marc Nabholtz; Marie-Ange Mouret-Reynier; Xavier Durando; Isabelle Van Praag; Béatrice Nayl; Jean-Pierre Ferriere; Philippe Chollet
Journal:  Indian J Surg Oncol       Date:  2010-08-07

Review 6.  Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.

Authors:  Tatjana Elène Vogelvang; Marius Jan van der Mooren; Velja Mijatovic; Peter Kenemans
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Surgical Methods for the Treatment of Uterine Fibroids - Risk of Uterine Sarcoma and Problems of Morcellation: Position Paper of the DGGG.

Authors:  M W Beckmann; I Juhasz-Böss; D Denschlag; P Gaß; T Dimpfl; P Harter; P Mallmann; S P Renner; S Rimbach; I Runnebaum; M Untch; S Y Brucker; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-02       Impact factor: 2.915

8.  Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics.

Authors:  Vineetha Koroth Edavana; Ishwori B Dhakal; Suzanne Williams; Rosalind Penney; Gunnar Boysen; Aiwei Yao-Borengasser; Susan Kadlubar
Journal:  Drug Metab Dispos       Date:  2013-01-31       Impact factor: 3.922

9.  Uterine Corpus Malignancies in Appalachia Kentucky: Incidence, Survival, and Related Health Disparities.

Authors:  Marian Symmes Johnson; Thomas C Tucker; Quan Chen; Bin Huang; Christopher P DeSimone; Rachel W Miller; Lauren A Baldwin; Tricia I Fredericks; Brian T Burgess; Frederick R Ueland
Journal:  South Med J       Date:  2020-01       Impact factor: 0.954

10.  Uterine sarcoma: a clinical case and a literature review.

Authors:  Diana Bužinskienė; Saulius Mikėnas; Gražina Drąsutienė; Matas Mongirdas
Journal:  Acta Med Litu       Date:  2018
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.